Cargando…

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Detalles Bibliográficos
Autor principal:	Lamb, Yvette N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217034/ https://www.ncbi.nlm.nih.gov/pubmed/34050918 http://dx.doi.org/10.1007/s40265-021-01543-9

Ejemplares similares

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Correction: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
por: Cutolo, Maurizio, et al.
Publicado: (2023)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Correction: Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Progressive fibrotic interstitial lung disease
por: Pereira, Carlos A C, et al.
Publicado: (2023)

Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy
por: Kasam, Rajesh K., et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Eftrenonacog Alfa: A Review in Haemophilia B
por: Lamb, Yvette N., et al.
Publicado: (2023)

Correction to: clinical significance of high monocyte counts for the continuous treatment with nintedanib
por: Tsuneyoshi, Shingo, et al.
Publicado: (2023)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
por: Schmid, Ulrike, et al.
Publicado: (2021)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
por: Toellner, Hannah, et al.
Publicado: (2017)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Correction to: Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2023)

Transbronchial Lung Cryobiopsy in the Diagnosis of Fibrotic Interstitial Lung Diseases
por: Casoni, Gian Luca, et al.
Publicado: (2014)

Tracheobronchopathia Osteochondroplastica Associated with Fibrotic Interstitial Lung Disease
por: Heo, Jung Won, et al.
Publicado: (2021)

Unmet Needs for Palliation in Fibrotic Interstitial Lung Disease
por: Singhania, Sumeet Vimal Kishore, et al.
Publicado: (2018)

Clinical Overview of Progressive Fibrotic Interstitial Lung Disease
por: Case, Amy Hajari
Publicado: (2022)

Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease
por: Berger, Kristin, et al.
Publicado: (2023)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Correction to: Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use
por: Lamb, Yvette N.
Publicado: (2019)

The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials
por: Chen, Chao-Hsien, et al.
Publicado: (2021)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Fibrotic interstitial lung diseases and air pollution: a systematic literature review
por: Harari, Sergio, et al.
Publicado: (2020)

Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study
por: Guler, Sabina A., et al.
Publicado: (2022)

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug
por: Kafle, Sunam, et al.
Publicado: (2021)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fm3sv2qbkmk7c2qmfehismrdn5